Nasonex Nasal Spray: Relief from Allergic Rhinitis Symptoms
| Dos produk: 18g | |||
|---|---|---|---|
| Pakej (bil.) | Per sprayer | Harga | Beli |
| 2 | $31.01 | $62.02 (0%) | 🛒 Tambah ke troli |
| 3 | $30.01 | $93.03 $90.03 (3%) | 🛒 Tambah ke troli |
| 4 | $29.26 | $124.04 $117.04 (6%) | 🛒 Tambah ke troli |
| 5 | $28.61 | $155.05 $143.05 (8%) | 🛒 Tambah ke troli |
| 6 | $28.34 | $186.06 $170.06 (9%) | 🛒 Tambah ke troli |
| 7 | $28.01 | $217.07 $196.06 (10%) | 🛒 Tambah ke troli |
| 8 | $27.88 | $248.08 $223.07 (10%) | 🛒 Tambah ke troli |
| 9 | $27.79 | $279.09 $250.08 (10%) | 🛒 Tambah ke troli |
| 10 | $27.61
Terbaik per sprayer | $310.10 $276.09 (11%) | 🛒 Tambah ke troli |
Sinonim | |||
Nasonex Nasal Spray (mometasone furoate monohydrate) is a prescription corticosteroid spray indicated for the management of nasal symptoms of seasonal and perennial allergic rhinitis in adults and pediatric patients. It works locally in the nasal passages to reduce inflammation, providing effective, non-sedating relief from congestion, sneezing, runny nose, and nasal itching. Its once-daily dosing regimen supports treatment adherence and offers a favorable safety profile for appropriate patients under medical supervision.
Features
- Active ingredient: Mometasone furoate monohydrate equivalent to mometasone furoate 50 mcg per spray
- Delivery system: Metered-dose, manual pump spray bottle
- Volume: 17 g (approximately 120 sprays per bottle after priming)
- Preservative: Benzalkonium chloride
- pH: Adjusted to approximately 4.5
- Device characteristics: Includes safety clip, clear dosing window, and ergonomic actuator
Benefits
- Provides significant reduction in nasal inflammation and associated allergic symptoms
- Offers 24-hour symptom control with a single daily administration
- Minimizes systemic absorption due to low bioavailability (<0.1%)
- Non-sedating formula allows for unimpaired daytime functioning
- Suitable for long-term management of chronic allergic rhinitis
- Reduces nasal polyp size in indicated cases
Common use
Nasonex is primarily prescribed for the treatment of nasal symptoms associated with seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis in patients 2 years of age and older. It is also approved for the prophylaxis of seasonal allergic rhinitis symptoms when initiated 2-4 weeks prior to anticipated pollen exposure. Additionally, it is indicated for the treatment of nasal polyps in patients 18 years of age and older, helping to reduce polyp size and improve nasal airflow.
Dosage and direction
For allergic rhinitis in adults and adolescents 12 years and older: 2 sprays (100 mcg) in each nostril once daily (total daily dose 200 mcg). Once symptoms are controlled, dose may be reduced to 1 spray per nostril daily. For children 2-11 years: 1 spray (50 mcg) in each nostril once daily (total daily dose 100 mcg). For nasal polyps in adults: 2 sprays in each nostril twice daily (total daily dose 400 mcg). Shake well before use. Prime pump before first use by pressing 10 times until fine spray appears. If not used for 14 days or longer, reprime with 2 sprays. Blow nose gently before use. Insert tip into nostril, pointing away from nasal septum, and spray while breathing in gently through nose.
Precautions
Use with caution in patients with recent nasal septum ulcers, nasal surgery, or nasal trauma. Monitor patients for signs of localized fungal infections. Caution advised in patients with tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex. Periodic examinations of the nasal mucosa are recommended during long-term therapy. Not for ophthalmic use. Systemic corticosteroid effects may occur with excessive doses. Patients transferring from systemic corticosteroids may experience withdrawal symptoms. Growth velocity should be monitored in pediatric patients.
Contraindications
Hypersensitivity to mometasone furoate or any component of the formulation. Contraindicated in patients with untreated localized infections involving the nasal mucosa. Not recommended for the treatment of non-allergic rhinitis. Should not be used for emergency treatment of acute bronchospasm.
Possible side effects
Common side effects (≥1%): headache, nasal irritation, pharyngitis, epistaxis (blood-tinged mucus), nasal burning. Uncommon side effects: nasal ulceration, perforation of nasal septum, increased intraocular pressure, glaucoma, cataracts. Rare cases of immediate and delayed hypersensitivity reactions including urticaria, angioedema, rash, and bronchospasm have been reported. Fungal infections of nose and pharynx may occur.
Drug interaction
Formal drug interaction studies have not been conducted with Nasonex Nasal Spray. However, caution is advised with concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) due to potential increased systemic exposure to mometasone. No clinically significant interactions with commonly prescribed medications have been reported, but healthcare providers should be informed of all concurrent medications.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consistent daily use provides optimal therapeutic effect.
Overdose
Acute overdose is unlikely due to low systemic bioavailability. Single doses up to 20 times the recommended dose have been administered without adverse effects. Chronic excessive use may lead to systemic corticosteroid effects including hypercorticism and adrenal suppression. Treatment should be symptomatic and supportive. There is no specific antidote.
Storage
Store at room temperature (15-30°C). Do not freeze. Keep bottle upright. Protect from light. Keep out of reach of children. Discard after 120 actuations following initial priming, as the amount of mometasone per spray thereafter may be substantially less than 50 mcg. Do not store in extreme temperatures or humid conditions.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Nasonex is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Individual results may vary. Patients should read the package insert thoroughly and consult their physician regarding appropriate use, potential risks, and benefits based on their specific medical condition.
Reviews
Clinical studies demonstrate Nasonex significantly improves nasal symptom scores compared to placebo, with onset of action within 12 hours for some symptoms and maximal effect typically achieved within 1-2 weeks of regular use. In pediatric studies, Nasonex showed significant improvement in total nasal symptom scores with a safety profile comparable to placebo. Long-term studies (up to 12 months) support its maintained efficacy and safety for chronic management. Patient satisfaction surveys indicate high rates of satisfaction with symptom control and convenience of once-daily dosing.